SIRPA and mycosis fungoides: The only “monotherapy” to succeed to date against patient tumors is an intratumorally administered SIRPα-IgG1 chimera in fungoides mycosis (a type of lymphoma), with evidence that the IgG1 serves to opsonize while SIRPα binds CD47 [37,38].